CSI Market
Sign In | Register

Sangui Biotech International Inc (SGBI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SGBI Annual Cash Flow →
Tracking cash flow results across Sangui Biotech International Inc to Mar 31 2022 helps illustrate how Mar 31 2023's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2023)
9 Months 		(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Operating Activities
Income-0.12
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.03
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease-
Stockholders Equity Period Increase Decrease-
Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued-
Other General And Administrative Expense-
Inventory Net-
Prepaid Expense And Other Assets-
Related Party Transaction Due From To Related Party-
Income Loss Attributable To Parent-
Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority-
Translation Adjustment Functional To Reporting Currency Net Of Tax Period Increase Decrease-
Debt Instrument Increase Decrease Other Net-
Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Adjustment-
Loss On Out Of Court Settlement-
Amortization Of Right To Use Asset0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.01
Accounts Payable0.06
Accrued Expense0.00
Increase (Decrease) in Customer Advances0.00
Increase (Decrease) in Prepaid Expense0.01
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.01
Discontinued operations0.00
Net Cash flow from Operating Activities-0.02
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Investment Projects0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses and Interest in Affiliates0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Increase (Decrease) in Lease Acquisition Costs-0.01
Other Net0.01
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.01
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Common Stock Shares Issued-
Treasury Stock Value Retired Cost Method-
Stock Issued During Period Shares Period Increase Decrease-
Convertible Debt-
Prepayment Fees On Advances Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.01
Effect of exchange rate on cash flow0.01
Discontinued operations0.00
Free Cash Flow-0.02
Total Cash Flow-0.02
4 historic quarters locked

Sign in to unlock the full Sangui Biotech International Inc cash flow history.

Sign In Create Free Account

About Sangui Biotech International Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001096906-23-001042

Figures are derived from filed reports and may be restated. Historical data is subject to revision.